Metraipolis › archive › dc_39d04e16fa60

Extended treatment of abrocitinib: evaluation of efficacy and safety in chronic actinic dermatitis — Europe PMC PMID:41716804

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41716804
DOI
10.3389/fmed.2026.1742273
License (as archived)
solo-consultazione
Archived
2026-11-06T03:06:50.335Z
SHA-256 of the archived text
5b93a6a4c435d04677f5dd432cbd02a6f072758420bfc650699b3dc77422211b
Stable URL of this page
https://metraipolis.com/documento/dc_39d04e16fa60

How to cite

Extended treatment of abrocitinib: evaluation of efficacy and safety in chronic actinic dermatitis — Europe PMC PMID:41716804 — Europe PMC (en), https://europepmc.org/article/MED/41716804 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_39d04e16fa60 (Metraipolis archive dc_39d04e16fa60, sha256 5b93a6a4c435d04677f5dd432cbd02a6f072758420bfc650699b3dc77422211b)
BibTeX
@misc{dc39d04e16fa60,
  title = {Extended treatment of abrocitinib: evaluation of efficacy and safety in chronic actinic dermatitis — Europe PMC PMID:41716804},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41716804},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_39d04e16fa60; sha256 5b93a6a4c435d04677f5dd432cbd02a6f072758420bfc650699b3dc77422211b},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41716804. Agents can read the archived copy with the MCP tool read_document.